Anti-angiogenesis for cancer: Current status and prospects

Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis

Peter C. Maisonpierre, Chitra Suri, Pamela F. Jones et al. · Science · 1997 · 3.6K citations

Life Sciences, Developmental Biology, Molecular Biology +16

Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer

Lin Zhang, José R. Conejo-García, Dionyssios Katsaros et al. · New England Journal of Medicine · 2003 · 3.4K citations · Full text

Medicine, Immunology, Oncology +17

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

Robert A. Burger, Mark F. Brady, Michael A. Bookman et al. · New England Journal of Medicine · 2011 · 2.4K citations · Full text

Medicine, Gynecology, Oncology +11

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Timothy Perren, Ann Marie Swart, Jacobus Pfisterer et al. · New England Journal of Medicine · 2011 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +11

AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer

Stephen R. Wedge, Jane Kendrew, Laurent Hennequin et al. · Cancer Research · 2005 · 711 citations · Full text

Medicine, Oncology, Pharmacology +17